Concepedia

Jun Shen

JS

Statistics

Publications

7

Citations

626

H-Index

7

Active since

2012

Affiliations

Bristol-Myers Squibb (United States)(Current)

Jun Shen is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2012–2021

7

Publications

7

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska et al. · Annals of Oncology · 2017 · 231 citations · Full text

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Anjaneya Chimalakonda, James R. Burke, Lihong Cheng et al. · Dermatology and Therapy · 2021 · 118 citations · Full text

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

Birgit Geoerger, Christophe Bergeron, Lia Gore et al. · European Journal of Cancer · 2017 · 94 citations

, , +7

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

Xiaochen Zhao, Jun Shen, Vijay Ivaturi et al. · Annals of Oncology · 2020 · 87 citations · Full text

Time-Varying Belatacept Exposure and Its Relationship to Efficacy/Safety Responses in Kidney-Transplant Recipients

Zexun Zhou, Jun Shen, Yanlong Hong et al. · Clinical Pharmacology & Therapeutics · 2012 · 39 citations

, , +17

1–5 of 7